
Opinion|Videos|May 1, 2025
Optimizing Genomic Testing in Breast Cancer: Strategies for Community Practitioners
Panelists discuss how community practitioners face challenges with genomic testing due to working across multiple hospitals with different medical oncology groups who may have varying preferences for assays, emphasizing the importance of communication, established algorithms, and leveraging partnerships with testing companies.
Advertisement
Practical Implementation and Community Practice Challenges
Main Discussion Topics:
- Challenges faced by community practitioners regarding genomic testing
- Implementation of reflex testing strategies based on pathological criteria
- Billing, reimbursement, and ordering logistics in different practice settings
Key Points for Physicians:
- Community practitioners often work across multiple hospitals with different medical oncology groups who may have different testing preferences.
- Electronic portal-based ordering systems and electronic medical record integration improve workflow efficiency.
- Relationships with testing companies can help address reimbursement and coding issues.
Notable Insights:
- Some institutions implement reflex testing criteria based on T and N staging and patient age to improve efficiency.
- Testing companies can be valuable partners in ensuring appropriate coding and test selection.
Clinical Significance: Successful implementation of genomic testing in community settings requires robust communication systems, clear algorithms, and attention to billing/reimbursement considerations to ensure appropriate test utilization.
Advertisement
Related to this article

Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.

A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.

Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.

Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.

Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Advertisement
Advertisement
Trending on OncLive
1
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
5

